CD36 and Alzheimer disease: In general, AD therapeutic strategies targeting CD36 have two main focuses: CD36 blockade with neutralizing antibodies or other small molecules to suppress the inflammatory response of microglia, and upregulating the expression of CD33 to lower the Aβ burden, respectively.